Form 4: Prothena Corp Public Ltd Co: Officer Garren Hideki Reports Stock Option Grant

Hideki Garren, Chief Medical Officer of Prothena Corp Public Ltd Co, reports the acquisition of stock options for 85,000 ordinary shares.

Summary

• On February 27, 2024, Hideki Garren, the Chief Medical Officer of Prothena Corp Public Ltd Co, was granted stock options for 85,000 ordinary shares.
• The exercise price of these options is $30.30.
• The options vest over a period of four years, with 25% vesting on February 27, 2025, and the remainder vesting in equal monthly installments thereafter, contingent upon continued employment.
• The options expire on February 27, 2034.
• Following this transaction, Garren directly owns options for 85,000 ordinary shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to an executive. It's a standard practice and doesn't necessarily indicate positive or negative performance.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued employment and contribution to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The size of the grant and the vesting schedule are typical for a Chief Medical Officer at a company like Prothena.
• Comparing the vesting schedule and exercise price to similar companies would provide a more detailed assessment of the competitiveness of this compensation package.

Stakeholder Impact

• The stock option grant could potentially incentivize the Chief Medical Officer to drive company performance, benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates